A Review of the Rational and Current Evidence on Colchicine for COVID-19

被引:2
|
作者
Ghaith, Hazem S. [1 ]
Gabra, Mohamed Diaa [2 ]
Nafady, Mohamed H. [3 ]
Elshawah, Hamza Emad [4 ]
Negida, Ahmed [5 ,6 ]
Mushtaq, Gohar [7 ]
Kamal, Mohammad Amjad [8 ,9 ,10 ,11 ]
机构
[1] Al Azhar Univ, Fac Med, Cairo, Egypt
[2] South Valley Univ, Fac Med, Qena, Egypt
[3] Misr Univ Sci & Technol, Fac Appl Med Sci, 6th October City, Egypt
[4] Al Azhar Univ, Fac Med, New Damietta, Egypt
[5] Zagazig Univ, Fac Med, Zagazig, Egypt
[6] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, England
[7] Idlib Univ, Fac Med, Ctr Sci Res, Idlib, Syria
[8] Sichuan Univ, West China Hosp, Inst Syst Genet, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[9] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia
[10] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka 1207, Bangladesh
[11] Enzymoics, Novel Global Community Educ Fdn, 7 Peterlee Pl, Hebersham, NSW 2770, Australia
关键词
Anti-inflammatory agents; immunosuppressive agents; immune modulators; colchicine; COVID-19; SARS-CoV-2; CORONAVIRUS; PROTEIN; ACE2;
D O I
10.2174/1381612827666211210142352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current coronavirus disease (COVID-19) pandemic has affected millions of individuals worldwide. Despite extensive research efforts, few therapeutic options currently offer direct clinical benefits for COVID-19 patients. Despite the advances in our understanding of COVID-19, the mortality rates remain significantly high owing to the high viral transmission rates in several countries and the rise of various mutations in the SARS-CoV-2. One currently available and widely used drug that combines both anti-inflammatory and immunomodulatory actions is colchicine, which has been proposed as a possible treatment option for COVID-19. Colchicine still did not get much attention from the medical and scientific communities despite its anti-inflammatory and immunomodulatory mechanisms of action and positive preliminary data from early trials. This literature review article provides the scientific rationale for repurposing colchicine as a potential therapy for COVID-19. Further, we summarize colchicine's mechanisms of action and possible roles in COVID-19 patients. Finally, we supplement this review with a summary of the doses, side effects, and early efficacy data from clinical trials to date. Despite the promising early findings from multiple observational and clinical trials about the potential of colchicine in COVID-19, the data from the RECOVERY trial, the largest COVID-19 randomized controlled trial (RCT) in the world, showed no evidence of clinical benefits in mortality, hospital stays, or disease progression (n = 11340 patients). However, multiple other smaller clinical trials showed significant clinical benefits. We conclude that while current evidence does not support the use of colchicine for treating COVID-19, the present body of evidence is heterogeneous and inconclusive. The drug cannot be used in clinical practice or abandoned from clinical research without additional large RCTs providing more robust evidence. At present, the drug should not be used except for investigational purposes.
引用
收藏
页码:3194 / 3201
页数:8
相关论文
共 50 条
  • [21] Ocular manifestations of COVID-19: A systematic review of current evidence
    Seyedalinaghi, SeyedAhmad
    Mehraeen, Esmaeil
    Afzalian, Arian
    Dashti, Mohsen
    Ghasemzadeh, Afsaneh
    Pashaei, Ava
    Afsahi, Amir Masoud
    Zadeh, Seyed Saeed Tamehri
    Fard, Iman Amiri
    Vafaee, Amirmohammad
    Molla, Ayoob
    Shahidi, Ramin
    Dadjou, Ali
    Habibi, Mohammad Amin
    Mirzapour, Pegah
    Dadras, Omid
    PREVENTIVE MEDICINE REPORTS, 2024, 38
  • [22] Genetic susceptibility of COVID-19: a systematic review of current evidence
    SeyedAhmad SeyedAlinaghi
    Mohammad Mehrtak
    Mehrzad MohsseniPour
    Pegah Mirzapour
    Alireza Barzegary
    Pedram Habibi
    Banafsheh Moradmand-Badie
    Amir Masoud Afsahi
    Amirali Karimi
    Mohammad Heydari
    Esmaeil Mehraeen
    Omid Dadras
    Jean-Marc Sabatier
    Fabricio Voltarelli
    European Journal of Medical Research, 26
  • [23] Current Options in the Treatment of COVID-19: A Review
    Teimury, Azadeh
    Khaledi, Elahe Mahmoodi
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2020, 13 : 1999 - 2010
  • [24] Review of Current Diagnostics Developed for COVID-19
    Daneshpour, Maryam
    Mazhari, Zhina
    Mohammadi, Melika Haji
    Cetin, Arif E.
    Khodamoradi, Maedeh
    Aref, Amir Reza
    Azimzadeh, Mostafa
    Topkaya, Seda Nur
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY RESEARCH, 2021, 8 (04): : 417 - 444
  • [25] Treatment and prognosis of COVID-19: Current scenario and prospects (Review)
    Li, Xuemei
    Li, Tao
    Wang, Huihui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
  • [26] A Systematic Review of COVID-19 Epidemiology Based on Current Evidence
    Park, Minah
    Cook, Alex R.
    Lim, Jue Tao
    Sun, Yinxiaohe
    Dickens, Borame L.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [27] COVID-19 and smoking: A systematic review of the evidence
    Vardavas, Constantine I.
    Nikitara, Katerina
    TOBACCO INDUCED DISEASES, 2020, 18
  • [28] Impact of COVID-19 on Cardiovascular Patients and Review of Current COVID-19 Treatment Strategies
    Alfawaz, Dalal A.
    Alfawaz, Mohammed
    Almutawa, Ali M.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2020, 32 (42) : 69 - 79
  • [29] The evidence from clinical trials on colchicine and corticosteroids' effect on COVID-19: a systematic review and meta-analysis
    Bitar, Ahmad Naoras
    Sulaiman, Syed Azhar Syed
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (12) : 2097 - 2108
  • [30] The role of colchicine in the management of COVID-19: a Meta-analysis
    Elshiwy, Kholoud
    Amin, Ghada Essam El-Din
    Farres, Mohamed Nazmy
    Samir, Rasha
    Allam, Mohamed Farouk
    BMC PULMONARY MEDICINE, 2024, 24 (01)